


Curriculum Vitae

Name	David Ross Camidge	
Current Position & Affiliation	Director of Thoracic Oncology, Joyce Zeff Chair in Lung Cancer Research University of Colorado Cancer Centre, Denver, USA	
Country	USA	

Educational Background

6/2005	USMLE STEP 3 [97(234)]
1/2005	ECFMG certified: #0-501-735-5
1992-1995	BM BCh (M.D. equivalent) Degrees John Radcliffe Hospital Oxford University, Oxford, UK
1988-1992	PhD (Molecular Biology), 'Studies on the adaptors of clathrin-coated vesicles' Laboratory of Dr B.M.F. Pearse Medical Research Council Laboratory of Molecular Biology Cambridge University, Cambridge, UK
1985-1988	BA Hons Degree Physiological Sciences (Medicine) Final Honor Schools: Cell Biology & Pharmacology St Johns College, Oxford University, Oxford, UK

Professional Experience

7/2015-Present	Professor with Tenure, Department of Medicine, Division of Medical Oncology, Thoracic Oncology and Developmental Therapeutics Programs, University of Colorado
7/2010-7/2015	Associate Professor of Medicine/Oncology, Thoracic Oncology and Developmental Therapeutics Programs University of Colorado
10/2007-7/2010	Assistant Professor of Medicine/Oncology, Thoracic Oncology and Developmental Therapeutics Programs University of Colorado

11/2005-10/2007 Visiting Assistant Professor of Medicine/Oncology
GSK-Cambridge University International Oncology Fellowship
University of Colorado

Hospital, Government or Other Professional Positions

3/2001-11/2005 Clinical Lecturer in Cancer Therapeutics (Medical Oncology & Clinical Pharmacology), Edinburgh Cancer Centre
University of Edinburgh, Edinburgh, UK

External attachments during Edinburgh University Clinical Lecturer position 2001-2005:

3/2003-8/2004 a) Oncology Research Physician and Translational Science Strategist
AstraZeneca Pharmaceuticals
Alderley Park, Macclesfield, UK

3/2003-8/2004 b) Honorary Specialist Registrar
Thoracic Malignancies Program (Prof. N. Thatcher)
Christie Hospital, Manchester, UK

9/1999-2/2001 Specialist Registrar
Radiation Oncology Program (Prof. A. Price and A. Gregor)
Edinburgh Cancer Centre, Edinburgh, UK

5/1999-8/1999 Locum Registrar
Hematology Program (Prof. G. Prentice and V. Hoffbrand)
Royal Free Hospital, London, UK

8/1998-4/1999 Senior House Officer (Postgraduate Medicine Rotation)
Hematology Program (Prof. J. Goldman) & Intensive Care Program (Prof. T. Evans)
Hammersmith Hospital & Royal Brompton Hospital, London, UK

8/1996-8/1998 Senior House Officer (General Medicine Rotation including Oncology)
Freeman Group of Hospitals, Newcastle-upon-Tyne, UK

2/1996-8/1996 House Officer (General Surgery)
University Department of Surgery (Prof. T. Cooke)
Glasgow Royal Infirmary, Glasgow, UK

8/1995-2/1996 House Officer (General Medicine),
Nuffield Department of Medicine (Prof. D. Sackett), John Radcliffe Hospital, Oxford, UK

Professional Organizations

2009-Present	Member, Colorado Clinical & Translational Sciences Institute (CCTSI)
2008-Present	Member, American Association for Cancer Research (AACR)
2007-Present	Member, International Association for the Study of Lung Cancer (IASLC)
2006-Present	Member, American Society of Clinical Oncology
2006-Present	Member, South West Oncology Group
2001-2005	Member, British Pharmacological Society
2001-2005	Member, Association of Cancer Physicians, United Kingdom
1995-Present	Member, British Medical Association

Main Scientific Publications

Peer-Reviewed Original Articles

1. **Camidge DR**, Pearse BMF. Cloning of Drosophila β -adaplin and its localisation on expression in mammalian cells. *Journal of Cell Science* 1994; 107:709-718
[PMID: 8006084](#)
2. Bellamy R, Beyers N, McAdam KP, Ruwende C, Gie R, Samaai P, Bester D, Meyer M, Corrah T, Collin M, **Camidge DR**, Wilkinson D, Hoal-Van Helden E, Whittle HC, Amos W, van Helden P, Hill AV. Genetic susceptibility to tuberculosis in Africans: A genome-wide scan. *Proc Natl Acad Sci USA* 2000; 97:8005-8009
[PMID: 10859364](#); [PMCID: PMC 16660](#)
3. **Camidge DR**, Kunkler IH. Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence. *Clinical Oncology* 2000; 12:272-273
[PMID: 11005698](#)
4. **Camidge R**, Ong E, Lucraft H. An aggressive intrasinusoidal lymphoma presenting with marked systemic disturbance but normal imaging studies; *Postgraduate Medical Journal* 2000; 76:103-104
[PMID: 10644390](#); [PMCID: PMC 1741498](#)
5. **Camidge DR**. The causes of dysphagia in carcinoma of the lung. *Journal of the Royal Society of Medicine* 2001; 94:567-572
[PMID: 11691893](#)
6. **Camidge R**, Peaston R. Recommended dose antacids and severe hypercalcaemia. *British Journal of Clinical Pharmacology* 2001; 52:341
[PMID: 11560570](#); [PMCID: PMC 2014540](#)
7. **Camidge DR**, Randall KR, Foster JR, Sadler CJ, Wright JA, Soames AR, Laud PJ, Smith PD, Hughes AM. Plucked human hair as a tissue in which to assess

- pharmacodynamic endpoints during drug development studies. *British Journal of Cancer* 2005; 92:1837-1841 PMID: 15886708
8. **Camidge R**, Reigner B, Cassidy J, Grange S, Abt M, Weidekamm E, Jodrell D. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. *Journal of Clinical Oncology* 2005; 23:4719-4725 PMID: 16034047
 9. **Camidge R**, Walker A, Oliver JJ, Nussey F, Maxwell S, Jodrell D, Webb DJ. Prognosis without treatment as a modifier in health economic assessments. *British Medical Journal* 2005; 330:1382-1384 PMID: 15947403; PMCID: PMC 558296
 10. **Camidge DR**, Pemberton MN, Growcott JW, Johnstone D, Laud PJ, Foster JR, Randall KJ, Hughes AM. Assessing proliferation, cell cycle arrest and apoptotic endpoints in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development. *British Journal of Cancer* 2005; 93:208-215 PMID: 15999099; PMCID: PMC 2361555
 11. **Camidge DR**, Davies MJ, Laud PJ, Marshall AL, Cockerill M, Smith PD, Hughes AM. Factors determining the optimal body site and method for obtaining punch biopsies of human skin as a tissue in which to assess pharmacodynamic and pharmacokinetic endpoints in oncology drug development studies. *Cancer Chemotherapy and Pharmacology* 2006; 57:52-58 PMID: 16032432
 12. **Camidge DR**, Stockton DL, Bain M. Factors affecting the mesothelioma detection rate within national and international epidemiological studies: Insights from Scottish linked cancer registry-mortality data. *British Journal of Cancer* 2006; 95:649-652 PMID: 16909142; PMCID: PMC 2360683
 13. **Camidge DR**, Stockton DL, Frame S, Wood R, Bain M, Bateman DN. Hospital admissions and deaths relating to deliberate self-harm and accidents within five years of a cancer diagnosis: A national study in Scotland, UK. *British Journal of Cancer* 2007; 96: 752-757 PMID: 17299389
 14. **Camidge DR**, Smethurst D, Growcott JW, Febbraro S, Swaisland H, Hughes AM. A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers. *Cancer Chemotherapy and Pharmacology* 2007; 60(3):391-398 PMID: 17115157
 15. **Camidge DR**, Pemberton M, Growcott JW, Amakye D, Wilson D, Swaisland H, Forder C, Wilkinson R, Byth K, Hughes AM. A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers. *Cancer Chemotherapy and Pharmacology* 2007; 60(4):479-488 PMID: 17143601
 16. **Camidge DR**, Eckhardt SG, Gore L, O'Bryant CL, Leong S, Basche M, Holden SN, Musib L, Baldwin J, Darstein C, Thornton D, Finn RS, Britten CD. A phase I safety, tolerability and pharmacokinetic study of enzastaurin combined with
-

- capecitabine in patients with advanced solid tumors. *Anti-Cancer Drugs* 2008; 19(1):77-84 PMID: 18043132
17. **Camidge DR**, Oliver JJ, Skinner C, Attwood B, Nussey F, Jodrell D, Webb DJ. The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes. *British Journal of Clinical Pharmacology* 2008; 65(2):224-229 PMID: 18251760 PMCID: PMC2291216
18. Cameron DA, **Camidge DR**, Oyee J, Hirsch M. Economic evaluation of Fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer. *British Journal of Cancer* 2008, (Epub ahead of print: November 18 2008) PMID: 19018261 PMCID: PMC 2607221
19. Erickson TM, Koeppe JR, Miller YE, Stuart RW, **Camidge DR**. Bronchioloalveolar Carcinoma Presenting as Chronic Progressive Pulmonary Infiltrates in a Woman with HIV: A diagnosis worth making. *Journal of Thoracic Oncology* 2008; 3(11):1353-1355 PMID: 18978572
20. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, Shepherd S, Stanley A, Sweeney A, Wilde J, Wheatley K; **WARP Collaborative Group, UK**. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. *Lancet* 2009; 373(9663):567-574. (Western General Hospital, Edinburgh (Center PI: Camidge): 5th highest accruing center of 68 contributing centers) PMID: 19217991
21. Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares S, **Camidge DR**. Is there a role for consolidative Stereotactic Body Radiation Therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. *Acta Oncologica* 2009; 48(4):578-583. PMID: 19373699
22. Kono SA, Weyant M, Franklin W, Gaspar L, **Camidge DR**. Second Opinion - Surprised by stage III: Unexpected N2 lymph node involvement found during surgery for early stage non-small cell lung cancer. *Oncology* 2009; 23(5):424-429. PMID: 19476276
23. Leong S, Cohen RB, Gustafson DL, Langer CJ, **Camidge DR**, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies. Results of a phase 1 and pharmacokinetic study. *Journal of Clinical Oncology* 2009; Aug 3 [Epub ahead of print] PMID: 19652058
24. Spratlin JL, Cohen RB, Eadens M, Gore L, **Camidge DR**, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor

- Receptor-2. *Journal of Clinical Oncology* 2010; 28(5):780-787. PMID: [20048182](#) PMID: PMC 2834394
25. **Camidge DR**, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Allison D, Bray G, Mendelson D. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. *Clinical Cancer Research* 2010; 16(4):1256-1263. PMID: [20145186](#)
26. Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, **Camidge DR**. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. *Investigational New Drugs* 2010 Jan 19. [Epub ahead of print] PMID: [20084425](#)
27. Banerji U, **Camidge DR**, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. *Clinical Cancer Research* 2010; 16(5):1613-1623. PMID: [20179232](#)
28. Zhang L, Kavanagh BD, Thorburn AM, **Camidge DR**. Preclinical and Clinical Estimates of a Cancer's Basal Apoptotic Rate Predict for the Amount of Apoptosis Induced by Subsequent Pro-Apoptotic Stimuli. *Clinical Cancer Research* 2010; 16(17):4478-4489 PMID: [20630997](#)
29. Goehle RW, Shultz JC, Murudkar C, Usanovic S, Lamour NF, Massey DH, Zhang L, **Camidge DR**, Shay JW, Minna JD, Chalfant CE. hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. *Journal of Clinical Investigation* 2010 Oct 25. [Epub ahead of print] PMID: [20972334](#)
30. Kwak EL, Bang YJ, **Camidge DR**, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *New England Journal of Medicine* 2010; 363:1693-1703 PMID: [20979469](#)
31. **Camidge DR**, Kono SA, Flacco A, Tan A-C, Doebele RC, Zhou Q, Crino L, Franklin WA, Varella-Garcia M. Optimizing the detection of lung cancer patients harboring Anaplastic Lymphoma Kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. *Clinical Cancer Research* 2010; 16(22):5581-5590. PMID: [21062932](#)
32. Ou SH, Bazhenova L, **Camidge DR**, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ.

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. *Journal of Thoracic Oncology* 2010; 5(12):2044-2046.

PMID: [21102269](#)

33. Janne P, Boss DS, **Camidge DR**, Britten CD, Engelman JA, Garon EB, Guo F, Wong SG, Liang JQ, Letrent SP, Millham R, Taylor I, Eckhardt SG, Schellens JH. Phase I Dose-escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors. *Clinical Cancer Research* 2011 Jan 10. [Epub ahead of print] PMID: [21220471](#)
34. Gandhi L, **Camidge DR**, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM. Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. *Journal of Clinical Oncology* 2011 Jan 31. [Epub ahead of print] PMID: [21282543](#)
35. **Camidge DR**, Kono SA, Lu X, Okuyama S, Baron AE, Oton AB, Davies AM, Varella-Garcia M, Franklin WA, Doebele RC. Anaplastic Lymphoma Kinase (ALK) gene rearrangements in non-small cell lung cancer are associated with prolonged progression free survival on pemetrexed. *Journal of Thoracic Oncology* 2011; 6(4):774-780. PMID: [21336183](#)
36. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, **Camidge DR**, Solomon BJ, Maki RG, Bang YJ, Kim DW, Christensen J, Tan W, Wilner KD, Salgia R, Iafrate AJ. Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification. *Journal of Thoracic Oncology* 2011; 6(5):942-946 PMID: [21623265](#)
37. Amin NP, Miften M, Kavanagh B, Raben D, **Camidge DR**, Thornton D, Rochford N, Gaspar LE. Impact of Induction Chemotherapy on Estimated Risk of Radiation Pneumonitis in Small Cell Lung Cancer. *Journal of Thoracic Oncology* 2011; 6(9):1553-1562 PMID: [21642862](#)
38. Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA Jr, **Camidge DR**. A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology* 2011; 29(26):3567-3573 PMID: [21825259](#)
39. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, **Camidge DR**. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a

- retrospective analysis. *Lancet Oncology* 2011 Sep 16. [Epub ahead of print] PMID: [21933749](#)
40. Chow LQ, Blais N, Jonker DJ, Laurie SA, Diab SG, Canil C, McWilliam M, Thall A, Ruiz-Garcia A, Zhang K, Tye L, Chao RC, **Camidge DR**. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. *Cancer Chemother Pharmacol*. 2011 Oct 12. [Epub ahead of print] PMID: [21989766](#)
41. Doebele RC, Pilling AB, Aisner D, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, **Camidge DR**. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer. *Clinical Cancer Research* 2012 2012 Mar 1;18(5):1472-82. PMID: [22235099](#)
42. Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, **Camidge DR**. A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer. *Journal of Thoracic Oncology* 2012 Jan 10. [Epub ahead of print] PMID: [22237261](#)
43. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, Aisner DL, Varella-Garcia M, **Camidge DR**. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. *Cancer*. 2012 Sep 15;118(18):4502-11 PMID: [22282022](#)
44. **Camidge DR**, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, Doebele RC, Barón AE, Varella-Garcia M. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. *Cancer*. 2012 2012 Sep 15;118(18):4486-94. PMID: [22282074](#)
45. Doebele RC, Conkling P, Traynor AM, Otterson GA, Zhao Y, Wind S, Stopfer P, Kaiser R, **Camidge DR**. A phase I, open-label, dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. *Annals of Oncology* 2012; doi: 10.1093/annonc/mdr596 PMID: [22345119](#)
46. Atherly AJ, **Camidge DR**. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. *British Journal of Cancer* 2012 Mar 13;106(6):1100-6. PMID: [22374459](#)
47. Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, **Camidge DR**. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal

- cell carcinoma and non-small cell lung cancer. *Investigational New Drugs* 2012 Mar 14. [Epub ahead of print] [PMID: 22415798](#)
48. Infante JR, **Camidge DR**, Mileskin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA, Siu LL. Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors. *Journal of Clinical Oncology* 2012 May 1;30(13):1527-33. [PMID: 22454420](#)
49. Weickhardt AJ, Rothman MS, Salian-Mehta S, Kiseljak-Vassiliades K, Oton AB, Doebele RC, Wierman ME, **Camidge DR**. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. *Cancer* 2012 Apr 4. doi: 10.1002/cncr.27450. [Epub ahead of print] [PMID: 22488744](#)
50. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, **Camidge DR**, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L. Phase 2 Study of Single Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer. *Clinical Cancer Research* 2012 Apr 11. [Epub ahead of print] [PMID: 22496272](#)
51. Leong S, Eckhardt SG, Chan E, Messersmith WA, Spratlin J, **Camidge DR**, Diab S, Khosravan R, Lin X, Chow Maneval E, Lockhart AC. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology* 2012 May 24. [Epub ahead of print] [PMID: 22623210](#)
52. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, **Camidge DR**, Varella-Garcia M, Doebele RC. Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer. *Clinical Cancer Research* 2012 Aug 23. [Epub ahead of print] [PMID: 22919003](#)
53. **Camidge DR**, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncol.* 2012 13(10):1011-9. [PMID: 22954507](#)
54. **Camidge DR**, Blais N, Jonker DJ, Soulières D, Doebele RC, Ruiz-Garcia A, Thall A, Zhang K, Laurie SA, Chao RC, Chow LQ. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. *Cancer Chemotherapy and Pharmacology* 2012 Oct 30. [Epub ahead of print] [PMID: 23108697](#)

55. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, **Camidge DR**. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. *Journal of Thoracic Oncology* 2012 Dec;7(12):1807-14. PMID: [23154552](#)
56. Yap TA, Arkenau HT, **Camidge DR**, George S, Serkova NJ, Gwyther SJ, Spratlin JL, Lal R, Spicer J, Desouza NM, Leach MO, Chick J, Poondru S, Boinpally R, Gedrich R, Brock K, Stephens A, Eckhardt SG, Kaye SB, Demetri G, Scurr M. First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies. *Clinical Cancer Research* 2013 Feb 15;19(4):909-19. PMID: [23403628](#)
57. Browning ET, Weickhardt AJ, **Camidge DR**. Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer. *Journal of Thoracic Oncology* 2013 Mar;8(3):e21. doi: 10.1097/JTO.0b013e31827a892c. PMID: [23407562](#)
58. Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez J-P, Shaw AT, Doebele RC, He S, Bates RC, **Camidge DR**, Morris SW, El-Hariry I, Proia DA. Targeted inhibition of the molecular chaperone HSP90 overcomes ALK inhibitor resistance in non-small cell lung cancer. *Cancer Discovery* 2013 (Epub ahead of print) PMID: [23533265](#)
59. Ohashi K, Sequis LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, **Camidge DR**, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA Jr, Pao W. Characteristics of Lung Cancers Harboring NRAS Mutations. *Clinical Cancer Research* 2013 Mar 20. [Epub ahead of print] PMID: [23515407](#)
60. Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou S-HI, **Camidge DR**. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. *Cancer* 2013 Jul 1;119(13):2383-90. PMID: [23585220](#)
61. Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, Lorusso PM, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, Lira ME, Schoenmakers EF, Christensen JG, **Camidge DR**. Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma. *Journal of Clinical Oncology* 2013 Apr 22. [Epub ahead of print] PMID: [23610116](#)
62. Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, de Pas T, Besse B, Solomon BJ, Blackhall F, Wu Y-L, Thomas M, O'Byrne KJ, Moro-Sibilot D, **Camidge DR**, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus Chemotherapy in Advanced ALK-rearranged Lung

- Cancer. *New England Journal of Medicine* 2013 368(25):2385-94. PMID: [23724913](#)
63. Berge EM, Lu X, Maxson D, Barón AE, Gadgeel SM, Solomon BJ, Doebele RC, Varella-Garcia M, **Camidge DR**. Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. *Clinical Lung Cancer* 2013 Aug 6. [Epub ahead of print] PMID: [23931899](#)
64. Blais N, **Camidge DR**, Jonker DJ, Soulières D, Laurie SA, Diab SG, Ruiz-Garcia A, Thall A, Zhang K, Chao RC, Chow LQ. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies-results of a phase I dose-escalation study. *Investigational New Drugs* 2013 Aug 22. [Epub ahead of print] PMID: [23963796](#)
65. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, **Camidge DR**, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffiatti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY; Response Assessment in Neuro-Oncology (RANO) group. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. *Lancet Oncology* 2013 Sep;14(10):e396-406. doi: 10.1016/S1470-2045(13)70311-5. PMID: [23993384](#)
66. Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffiatti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, **Camidge DR**, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY; Response Assessment in Neuro-Oncology (RANO) group. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. *Lancet Oncology* 2013 Sep;14(10):e407-16. doi: 10.1016/S1470-2045(13)70308-5. PMID: [23993385](#)
67. **Camidge DR**, Skokan M, Kiatsimkul P, Helfrich B, Lu X, Barón AE, Schulte N, Maxson D, Aisner DL, Franklin WA, Doebele RC, Varella-Garcia M. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: Implications for ALK inhibitor therapy. *Cancer*. 2013 Nov 15;119(22):3968-75. PMID: [24022839](#)
68. Brosnan EM, Weickhardt AJ, Lu X, Maxon DA, Barón AE, Chonchol M, **Camidge DR**. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. *Cancer*. 2013 Nov 20. doi: 10.1002/cncr.28478. [Epub ahead of print] PMID: [24258622](#)
69. Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA Jr, Heasley LE, Tan AC, **Camidge DR**, Varella-Garcia M, Doebele

- RC. Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer. *PLoS One* 2013 Dec 13;8(12):e82236. doi: 10.1371/journal.pone.0082236 PMID: 24349229
70. Besse B, Heist RS, Papadimitrakopoulou VA, **Camidge DR**, Beck JT, Schmid P, Mulatero C, Miller N, Dimitrijevic S, Urva S, Pylvaenäinen I, Petrovic K, Johnson BE. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. *Ann Oncol*. 2013 Dec 23. [Epub ahead of print] PMID: 24368401
71. Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, **Camidge DR**. Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib. *Int J Radiat Oncol Biol Phys*. 2014 Mar 15;88(4):892-8. PMID: 24462383
72. Reckamp KL, Giaccone G, **Camidge DR**, Gadgeel SM, Khuri FR, Engelman JA, Koczywas M, Rajan A, Campbell AK, Gernhardt D, Ruiz-Garcia A, Letrent S, Liang J, Taylor I, O'Connell JP, Jänne PA. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. *Cancer* 2014 Feb 5. [Epub ahead of print] PMID: 24501009
73. Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, **Camidge DR**. Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non-Small-Cell Lung Cancer. *J Thorac Oncol*. 2014 Mar;9(3):e21-3. PMID: 24518095
74. von Pawel J, Harvey JH, Spigel DR, Dediu M, Reck M, Cebotaru CL, Humphreys RC, Gribbin MJ, Fox NL, **Camidge DR**. Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer. *Clinical Lung Cancer*. 2013 Dec 27. pii: S1525-7304(13)00262-3. [Epub ahead of print] PMID: 24560012
75. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, **Camidge DR**, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med*. 2014 Mar 27;370(13):1189-97. PMID: 24670165
76. Wynes MW, Hinz TK, Gao D, Martini M, Marek L, Ware KE, Edwards MG, Bohm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, **Camidge DR**, Tan AC, Hirsch FR, Heasley LE. FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR

- TKI Sensitivity Across All Lung Cancer Histologies. *Clin Cancer Res.* 2014 Jun 15;20(12):3299-309. PMID: [24771645](#)
77. Browning ET, Huckleberry JM, Barrow WB, Restauri NL, Kemme DJ, Cool CD, Weyant MJ, Franklin WA, **Camidge DR**. Downstaging of Non-Small-Cell Lung Cancer Through Identification of Reversible Drug Toxicity. *J Clin Oncol.* 2014 May 5. [Epub ahead of print] PMID: [24799494](#)
78. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, **Camidge DR**, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA.* 2014 May 21;311(19):1998-2006. PMID: [24846037](#)
79. Levy B, Spira A, Becker D, Evans T, Schnadig I, **Camidge DR**, Bauman JE, Hausman D, Walker L, Nemunaitis J, Rudin CM, Halmos B, Bowles DW. A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non-Small-Cell Lung Cancer. *J Thorac Oncol.* 2014 Jul;9(7):1031-5 PMID: [24926548](#)
80. Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, **Camidge DR**, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations. *Cancer Discovery* 2014 Jul 29. [Epub ahead of print] PMID: [25074459](#)
81. Sharrocks K, Spicer J, **Camidge DR**, Papa S. The impact of socioeconomic status on access to cancer clinical trials. *Br J Cancer.* 2014 Aug 5. doi: 10.1038/bjc.2014.108. [Epub ahead of print] PMID: [25093493](#)
82. **Camidge DR**, Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz M Jr, Hoffman D, Spicer J, West H, Lee P, Yang L, Joshi A, Gao L, Yurasov S, Mita A. A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer. *J Thorac Oncol.* 2014 Aug 28. [Epub ahead of print] PMID: [25170639](#)
83. **Camidge DR**, Brosnan EM, DeSilva C, Koo PJ, Chonchol M. Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate. *J Thoracic Oncology* 2014 9(11):1634-7. PMID: [25436798](#)
84. Shaw AT, Ou S-H I, Bang Y-J, **Camidge DR**, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve M, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. *New England Journal of Medicine* 2014 Nov 20;371(21):1963-71. PMID:[25264305](#)

85. Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, **Camidge DR**, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. *Cancer*. 2014 Oct 1. [Epub ahead of print]. PMID: 25273224
86. Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, **Camidge DR**, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2014 Oct 27. [Epub ahead of print]. PMID: 25349291
87. Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J Jr, Cao D, Alexandris E, Yurasov S, **Camidge DR**, Bonomi P. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. *Cancer*. 2014 Nov 6. [Epub ahead of print]. PMID: 25377507
88. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, **Camidge DR**, Crinò L. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. *Journal of Clinical Oncology* 2015 Jan 26. pii: JCO.2014.59.0539. [Epub ahead of print]. PMID: 25624436
89. Kris MG, **Camidge DR**, Giaccone G, Hida T, Li BT, O'Connell J, Taylor I, Zhang H, Arcila ME, Goldberg Z, Jänne PA. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. *Annals of Oncology* 2015 Apr 21. pii: mdv186. [Epub ahead of print]. PMID: 25899785
90. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, **Camidge DR**. Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. *New England Journal of Medicine* 2015 Apr 30;372(18):1700-1709. PMID: 25923550
91. Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, **Camidge DR**, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K,

- Mehta MP, Schiff D, Soffiatti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY; Response Assessment in Neuro-Oncology (RANO) group. Response assessment criteria for brain metastases: proposal from the RANO group. *Lancet Oncology* 2015 Jun;16(6):e270-e278. PMID: 26065612
92. Narayanan V, Honce MJ, Mehrotra S, **Camidge DR**. Cystic Brain Metastases Occurring in Anaplastic Lymphoma Kinase Gene Rearranged Non-Small-Cell Lung Cancer Patients Receiving Crizotinib. *Clin Lung Cancer*. 2015 Jul 30. pii: S1525-7304(15)00183-7. doi: 10.1016/j.clc.2015.07.003. [Epub ahead of print]. PMID: 26314227
93. Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, **Camidge DR**, Contessa JN. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. *J Clin Oncol*. 2015 Oct 5. pii: JCO.2015.62.0138. [Epub ahead of print] PMID: 26438117
94. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, **Camidge DR**, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI; study investigators. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. *Lancet Oncol*. 2015 Dec 18. pii: S1470-2045(15)00488-X. doi: 10.1016/S1470-2045(15)00488-X. [Epub ahead of print]. PMID: 26708155
95. Womack JP, Varella-Garcia M, **Camidge DR**. Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure. *J Thorac Oncol*. 2015 Dec;10(12):e115-8. PMID: 26709484
96. McCoach CE, Berge EM, Lu X, Barón AE, **Camidge DR**. A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry. *J Thorac Oncol*. 2015 Dec 24. pii: S1556-0864(15)00047-7. [Epub ahead of print]. PMID: 26725180
97. Karlovich CA, Goldman J, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel DR, Soria JC, Solomon B, **Camidge DR**, Gadgeel SM, Paweletz CP, Wu L, Chien S, O'Donnell P, Matheny S, Despain D, Rolfe L, Raponi M, Allen AR, Park K, Wakelee HA. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase 1 study of rociletinib (CO-1686). *Clin Cancer Res*. 2016 Jan 8. pii: clincanres.1260.2015. [Epub ahead of print]. PMID: 26747242
98. Jänne PA, Shaw AT, **Camidge DR**, Giaccone G, Shreeve SM, Tang Y, Goldberg Z, Martini JF, Xu H, James LP, Solomon BJ. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced

- Non-small Cell Lung Cancer: Results of a Phase I Study. *J Thorac Oncol.* 2016 Feb 17. [Epub ahead of print]. PMID: 26899759
99. Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, **Camidge DR**, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. *Lancet Oncol.* 2016 Mar 10. [Epub ahead of print] PMID: 26973324
 100. Dziadziuszko R, Le AT, Wrona A, Jassem J, **Camidge DR**, Varella-Garcia M, Aisner DL, Doebele RC. An activating KIT mutation induces crizotinib resistance in ROS1 positive lung cancer. *J Thorac Oncol.* 2016 Apr 8. [Epub ahead of print] PMID: 27068398
 101. Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, **Camidge DR**, Doebele RC. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. *Lung Cancer.* 2016 Jun;96:27-32. doi: 10.1016/j.lungcan.2016.03.007. Epub 2016 Mar 26. PMID: 27133746
 102. Sequist LV, Soria JC, **Camidge DR**. Update to Rociletinib Data with the RECIST Confirmed Response Rate. *N Engl J Med.* 2016 May 11. [Epub ahead of print]. PMID: 27195670
 103. Noonan SA, Berry L, Lu X, Gao D, Barón AE, Chesnut P, Sheren J, Aisner DL, Merrick D, Doebele RC, Varella-Garcia M, **Camidge DR**. Identifying the appropriate FISH criteria for defining MET copy number driven lung adenocarcinoma through oncogene overlap analysis. *J Thorac Oncol.* 2016 2016 Aug;11(8):1293-1304. PMID: 2726221
 104. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, **Camidge DR**, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nat Commun.* 2016 Jun 10;7:11815. PMID: 27283993
 105. Damm-Welk C, Siddiqi F, Fischer M, Hero B, Narayanan V, **Camidge DR**, Harris M, Burke A, Lehrnbecher T, Pulford K, Oschlies I, Siebert R, Turner T, Woessmann W. Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK. *Journal of Cancer* 2016, 7(11): 1383-1387. PMID: 27471553
 106. Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, **Camidge DR**, Wakelee H, Perol M, Oxnard GR, Kosco K, Croucher P, Samuelsz E, Vibat CR, Guerrero S, Geis J, Berz D, Mann E, Matheny S, Rolfe L, Raponi M, Erlander MG, Gadgeel S. A Highly Sensitive and Quantitative Test Platform

- for Detection of NSCLC EGFR Mutations in Urine and Plasma. *J Thorac Oncol*. 2016 Jun 30. pii: S1556-0864(16)30587-1. doi: 10.1016/j.jtho.2016.05.035. [Epub ahead of print]. PMID: 27468937
107. Aisner DL, Rumery MD, Merrick DT, Kondo KL, Nijmeh H, Linderman DJ, Doebele RC, Thomas N, Chesnut PC, Varella-Garcia M, Franklin WA, **Camidge DR**. Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience. *Arch Pathol Lab Med*. 2016 Sep 9. [Epub ahead of print]. PMID: 27610643
108. Noonan SA, Sachs PB, **Camidge DR**. Brief report: Transient asymptomatic pulmonary opacities occurring during osimertinib treatment. *J Thorac Oncol*. 2016 Sep 9. pii: S1556-0864(16)30929-7. doi: 10.1016/j.jtho.2016.08.144. [Epub ahead of print]. PMID: 27618759
109. Caparica R, Yen CT, Coudry R, Ignatius Ou SH, Varella-Garcia M, **Camidge DR**, de Castro G Jr. Responses to crizotinib can occur in high level MET-amplified non-small cell lung cancer independent of MET exon 14 alterations: A brief report. *J Thorac Oncol*. 2016 Sep 21. pii: S1556-0864(16)31065-6. doi: 10.1016/j.jtho.2016.09.116. [Epub ahead of print]. PMID: 27664533
110. Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, **Camidge DR**, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. *Lancet Oncol*. 2016 Oct 24. pii: S1470-2045(16)30532-0. doi: 10.1016/S1470-2045(16)30532-0. [Epub ahead of print]. PMID: 27789196
111. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, **Camidge DR**. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. *Lancet Oncol*. 2016 Nov 7. [Epub ahead of print] PMID: 27836716
112. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, **Camidge DR**, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2016 Dec;34(34):4079-4085. PMID: 27863201
113. Becker DJ, Wisnivesky JP, Grossbard ML, Chachoua A, **Camidge DR**, Levy BP. Survival of Asian Females With Advanced Lung Cancer in the Era of

- Tyrosine Kinase Inhibitor Therapy. *Clin Lung Cancer*. 2016 Oct 5. [Epub ahead of print]. PMID: 28029530
114. Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, **Camidge DR**, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. *J Clin Oncol*. 2017 Jan 10;35(2):157-165. PMID: 27870574
115. Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, **Camidge DR**, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. *J Clin Oncol*. 2017 Jan 23 [Epub ahead of print]. PMID: 28113019
116. Jackson MW, Palma DA, **Camidge DR**, Jones BL, Robin TP, Sher DJ, Koshy M, Kavanagh BD, Gaspar LE, Rusthoven CG. The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma. *J Thorac Oncol*. 2017 Jan 25. [Epub ahead of print]. PMID: 28126540
117. York ER, Varella-Garcia M, Bang TJ, Aisner DL, **Camidge DR**. Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2017 Mar 6. pii: S1556-0864(17)30167-3. PMID: 28274743
118. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, **Camidge R**, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. *J Clin Oncol*. 2017 May 1;35(13):1403-1410. PMID: 28447912
119. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leigh NB, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, **Camidge DR**. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A

- Randomized, Multicenter Phase II Trial. *J Clin Oncol*. 2017 Aug 1;35(22):2490-2498. PMID: 28475456
120. Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, **Camidge DR**. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. *J Clin Oncol*. 2017 May 26;JCO2016721894. [Epub ahead of print]. PMID: 28548889
121. Peters S*, **Camidge DR*** Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. (*Equal contribution) Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 2017 Aug 31;377(9):829-838. PMID: 28586279
122. Gandhi L, Ignatius Ou SH, Shaw AT, Barlesi F, Dingemans AC, Kim DW, **Camidge DR**, Hughes BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. *Eur J Cancer*. 2017 Jun 21;82:27-33. [Epub ahead of print]. PMID: 28646771
123. Gray JE*, Heist RS*, Starodub AN*, **Camidge DR***, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM. (*Equal contribution) Therapy of Small-cell Lung Cancer (SCLC) With a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. *Clin Cancer Res*. 2017 Jul 5. pii: clincanres.0933.2017. doi: 10.1158/1078-0432.CCR-17-0933. [Epub ahead of print] PMID: 28679770
124. Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Barón AE, **Camidge DR**. Brief Report: Baseline and on treatment characteristics of serum tumor markers in stage IV oncogene-addicted adenocarcinoma of the lung. *J Thorac Oncol*. 2017 Aug 23. pii: S1556-0864(17)30680-9. doi: 10.1016/j.jtho.2017.08.005. [Epub ahead of print]. PMID: 28843358
125. Horn L, Gettinger S, **Camidge DR**, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. *Lung Cancer*. 2017 Nov;113:51-58. PMID: 29110849
126. Byers LA, Horn L, Ghandi J, Kloecker G, Owonikoko T, Waqar SN, Krzakowski M, Cardnell RJ, Fujimoto J, Taverna P, Azab M, **Camidge DR**. A

- phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients. *Oncotarget*. 2017 Aug 3;8(46):81441-81454. PMID: 29113403
127. Blackhall F, **Ross Camidge D**, Shaw AT, Soria JC, Solomon BJ, Mok T, Hirsh V, Jänne PA, Shi Y, Yang PC, Pas T, Hida T, Carpeño JC, Lanzalone S, Polli A, Iyer S, Reisman A, Wilner KD, Kim DW. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. *ESMO Open*. 2017 Aug 17;2(3):e000219. doi: 10.1136/esmoopen-2017-000219. eCollection 2017. PMID: 29209525
128. Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, **Camidge DR**, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. *Ann Oncol*. 2017 Dec 5. [Epub ahead of print] PMID: 29216356
129. Robin TP, **Camidge DR**, Stuhr K, Nath SK, Breeze RE, Pacheco J, Liu AK, Gaspar LE, Purcell WT, Doebele RC, Kavanagh BD, Rusthoven CG. Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer. *J Thorac Oncol*. 2017 Dec 18. pii: S1556-0864(17)33107-6. [Epub ahead of print] PMID: 29269007
130. **Camidge DR**, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffiatti R, van den Bent MJ, Wefel JS, Wen PY. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. *Lancet Oncol*. 2018 Jan;19(1):e20-e32. PMID: 29304358
131. McCoach CE, Le A, Gowan K, Jones KL, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, **Camidge DR**, Doebele RC. Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer. *Clin Cancer Res*. 2018 Apr 10. [Epub ahead of print] PMID: 29636358
132. Robin TP, Jones BL, Amini A, Koshy M, Gaspar LE, Liu AK, Nath SK, Kavanagh BD, **Camidge DR**, Rusthoven CG. Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer. *Lung Cancer*. 2018 Jun;120:88-90. PMID: 29748022
133. **Camidge DR**, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two

- Clinical Trials. *J Clin Oncol*. 2018 May 16;JCO2017775841. [Epub ahead of print] PMID: 29768119
134. **Camidge DR**, Sequist LV, Jänne PA, Weickhardt AJ, Dowling ES, Alicea J, Fan J, Oxnard GR. Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. *Clin Lung Cancer*. 2018 May 5. pii: S1525-7304(18)30097-4. doi: 10.1016/j.clcc.2018.04.015. [Epub ahead of print] PMID: 29861396
135. Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M, Purcell WT, Bowles DW, **Camidge DR**, Doebele RC. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. *J Thorac Oncol*. 2018 Jul 5. [Epub ahead of print] PMID: 29981925
136. Soria JC, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT, Blackhall F, Mok TS, Wu YL, Pestova K, Wilner KD, Polli A, Paolini J, Lanzalone S, Green S, **Camidge DR**. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small cell lung cancer. *Ann Oncol*. 2018 Jul 13. [Epub ahead of print] PMID: 30010763
137. Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, **Camidge DR**, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O. Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET-Rearranged Lung Cancers. *J Thorac Oncol*. 2018 Jul 11.[Epub ahead of print] PMID: 30017832
138. Liu SV, **Camidge DR**, Gettinger SN, Giaccone G, Heist RS, Hodi FS, Ready NE, Zhang W, Wallin J, Funke R, Waterkamp D, Foster P, Iizuka K, Powderly J. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. *Eur J Cancer*. 2018 Jul 24;101:114-122.[Epub ahead of print] PMID: 30053670
139. Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, **Camidge DR**, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. *Ann Oncol*. 2018 Jul 28. [Epub ahead of print] PMID: 30060089
140. Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, **Camidge DR**, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. *Cancer Discov*. 2018 Aug 9. [Epub ahead of print] PMID: 30093503

141. Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele RC, **Camidge DR**. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. *Clin Lung Cancer*. 2018 Aug 22. pii: S1525-7304(18)30205-5. [Epub ahead of print] PMID: 30197261
142. Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Pérol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nüesch E, Balas B, **Camidge DR**. Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. *Ann Oncol*. 2018 Sep 12. [Epub ahead of print] PMID: 30215676
143. Helman E, Nguyen M, Karlovich CA, Despain D, Choquette AK, Spira AI, Yu HA, **Camidge DR**, Harding TC, Lanman RB, Simmons AD. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. *Clin Lung Cancer*. 2018 Aug 7. pii: S1525-7304(18)30192-X. [Epub ahead of print] PMID: 30279111
144. **Camidge DR**, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Filip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018 Sep 25. [Epub ahead of print] PMID: 30280657
145. Ng TL, Yu H, Smith DE, Boyle TA, York ER, Leedy S, Gao D, Aisner DL, Van Bokhoven A, Heasley LE, Hirsch FR, **Camidge DR**. Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. *Clin Lung Cancer*. 2018 Sep 7. pii: S1525-7304(18)30234-1. [Epub ahead of print] PMID: 30297175
146. Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, Viteri S, Chae YK, **Camidge DR**, Gabrail NY, Hu B, Tian T, Nuthalapati S, Hoening E, He L, Komarnitsky P, Calles A. A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. *Clin Cancer Res*. 2018 Oct 16. [Epub ahead of print] PMID: 30327308
147. Solomon BJ, Besse B, Bauer TM, Filip E, Soo RA, **Camidge DR**, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ignatius Ou SH, Shaw AT. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. *Lancet Oncol*. 2018 Nov 6. pii: S1470-2045(18)30649-1. [Epub ahead of print] PMID: 30413378
148. Ng TL, Morgan RL, Patil T, Barón AE, Smith DE, **Ross Camidge D**. Detection of oligoprogressive disease in oncogene-addicted non-small cell

- lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor. *Lung Cancer*. 2018 Dec;126:112-118. doi: 10.1016/j.lungcan.2018.10.023. Epub 2018 Oct 23. PMID: 30527174
149. Ng TL, Smith DE, Mushtaq R, Patil T, Dimou A, Yang S, Liu Q, Li X, Zhou C, Jones RT, Tu MM, Yan F, Bowman IA, Liu SV, Newkirk S, Bauml J, Doebele RC, Aisner DL, Gao D, Ren S, **Camidge DR**. ROS1 gene rearrangements are associated with an elevated risk of peri-diagnosis thromboembolic events. *J Thorac Oncol*. 2018 Dec 10. pii: S1556-0864(18)33509-3. doi: 10.1016/j.jtho.2018.12.001. [Epub ahead of print] PMID: 30543838
150. Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, Jiang T, Su C, Wu C, Ren S, Zhou C, **Camidge DR**. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. *Cancer*. 2018 Dec 11. doi: 10.1002/cncr.31871. [Epub ahead of print] PMID: 30548240
151. Sakamoto MR, Honce JM, Lindquist DL, **Camidge DR**. Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. *Clin Lung Cancer*. 2018 Nov 29. pii: S1525-7304(18)30306-1. doi: 10.1016/j.clcc.2018.11.010. [Epub ahead of print]. PMID: 30578110
152. Wang Y, Jiang T, Qin Z, Jiang J, Wang Q, Yang S, Rivard C, Gao G, Ng TL, Tu MM, Yu H, Ji H, Zhou C, Ren S, Zhang J, Bunn P, Doebele RC, **Camidge DR**, Hirsch FR. HER2 exon 20 insertions in Non-Small Cell Lung Cancer are Sensitive to the Irreversible Pan-HER Receptor Tyrosine Kinase Inhibitor Pyrotinib. *Ann Oncol*. 2018 Dec 31. doi: 10.1093/annonc/mdy542. [Epub ahead of print] PMID: 30596880
153. Pacheco JM, Gao D, Smith D, Purcell WT, Hancock M, Bunn PA, Robin TP, Liu AK, Karam S, Gaspar LE, Kavanagh BD, Rusthoven CG, Aisner DL, Doebele RC, **Camidge DR**. Natural history and factors associated with overall survival in stage IV ALK rearranged non-small-cell lung cancer. *J Thorac Oncol*. 2018 Dec 29. pii: S1556-0864(18)33533-0. [Epub ahead of print] PMID: 30599201
154. Davies KD, Lomboy A, Lawrence CA, Yourshaw M, Bocsi GT, **Camidge DR**, Aisner DL. Brief Report: DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer. *J Thorac Oncol*. 2019 Jan 9. pii: S1556-0864(19)30007-3. [Epub ahead of print] PMID: 30639620
155. Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, Jia Y, Shi J, Zhang L, Liu X, Qiao M, Chen X, Su C, Yu H, Zhou C, Zhang J, **Camidge DR**, Hirsch FR. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer. *Cancer Immunol*

- Res. 2019 Feb 12. pii: canimm.0640.2017 [Epub ahead of print] PMID: 30755403
156. **Camidge DR**, Kim EE, Usari T, Polli A, Lewis I, Wilner KD. Renal Effects of Crizotinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2019 Feb 26. pii: S1556-0864(19)30146-7. [Epub ahead of print] PMID: 30822515
157. Weiss J, Kavanagh B, Deal A, Villaruz L, Stevenson J, **Camidge R**, Borghaei H, West J, Kirpalani P, Morris D, Lee C, Pecot CV, Zagar T, Stinchcombe T, Pennell N. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. *Cancer Treat Res Commun*. 2019 Feb 26;19:100126. [Epub ahead of print] PMID: 30852467
158. Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, **Camidge DR**, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2019 Mar 20;JCO1802236. [Epub ahead of print] PMID: 30892989
159. **Camidge DR**, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study. *J Thorac Oncol*. 2019 Mar 19. pii: S1556-0864(19)30210-2. [Epub ahead of print] PMID: 30902613
160. Shaw AT, Riely GJ, Bang YJ, Kim DW, **Camidge DR**, Varella-Garcia M, Lafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. *Ann Oncol*. 2019 Apr 13. pii: mdz131. doi: 10.1093/annonc/mdz131. [Epub ahead of print] PMID: 30980071
161. Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, **Camidge DR**, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. *J Clin Oncol*. 2019 May 8 [Epub ahead of print]. PMID: 31067138
162. Pritchett MA, **Camidge DR**, Patel M, Khatri J, Boniol S, Friedman EK, Khomani A, Dalia S, Baker-Neblett K, Plagnol V, Howarth KD, Jones GR, Rosenfeld R, Morris CD, Govindan R. Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of

- Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer. *JCO Precision Oncology* 2019 :3, 1-15
163. **Camidge DR**, Pabani A, Miller RM, Rizvi NA, Bazhenova L. Management strategies for early onset pulmonary events associated with brigatinib. *J Thorac Oncol.* 2019 May 17. pii: S1556-0864(19)30371-5. [Epub ahead of print] PMID: 31108247
164. Mazières J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascoux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, **Camidge DR**, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol.* 2019 May 24. pii: mdz167. [Epub ahead of print] PMID: 31125062
165. Ladbury CJ, Rusthoven CG, **Camidge DR**, Kavanagh BD, Nath SK. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiotherapy. *Int J Radiat Oncol Biol Phys.* 2019 Jun 5. pii: S0360-3016(19)30818-1. [Epub ahead of print] PMID: 31175902
166. Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, **Camidge DR**, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. *Lung Cancer.* 2019 Jul;133:96-102. Epub 2019 May 11. PMID: 31200835
167. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas V, Wolff AM, Fraser JS, Collisson EA, McCoach CE, **Camidge DR**, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer. *Clin Cancer Res.* 2019 Sep 23. [Epub ahead of print] PMID: 31548343
168. Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, Antonia SJ, Ascierto PA, Moreno V, Atmaca A, Salvagni S, Taylor M, Amin A, **Camidge DR**, Horn L, Calvo E, Li A, Lin WH, Callahan MK, Spigel DR. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. *J Thorac Oncol.* 2019 Oct 17. pii: S1556-0864(19)33531-2. [Epub ahead of print] PMID: 31629915
169. Gerber DE, **Camidge DR**, Morgensztern D, Cetnar J, Kelly RJ, Ramalingam SS, Spigel DR, Jeong W, Scaglioni PP, Zhang S, Li M, Weaver DT, Vaikus L,

- Keegan M, Horobin JC, Burns TF. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. *Lung Cancer*. 2019 Nov 4;139:60-67. [Epub ahead of print] PMID: 31739184
170. Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, Ahn MJ, Kim ES, Kerstein D, Groen HJM, **Camidge DR**. Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. *J Thorac Oncol*. 2019 Nov 19. pii: S1556-0864(19)33645-7. [Epub ahead of print] PMID: 31756496
171. Clark JW, **Camidge DR**, Kwak EL, Maki RG, Shapiro GI, Chen I, Tan W, Randolph S, Christensen JG, Ozeck M, Tang Y, Wilner KD, Salgia R. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. *Future Oncol*. 2019 Nov 28. [Epub ahead of print] PMID: 31778074
172. Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, **Camidge DR**, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2019 Nov 21. pii: S1525-7304(19)30325-0. [Epub ahead of print] PMID: 31859066
173. Drilon A, Clark JW, Weiss J, Ou SI, **Camidge DR**, Solomon BJ, Otterson GA, Villaruz LC, Riely GJ, Heist RS, Awad MM, Shapiro GI, Satouchi M, Hida T, Hayashi H, Murphy DA, Wang SC, Li S, Usari T, Wilner KD, Paik PK. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. *Nature Medicine* 2020 Jan;26(1):47-51.. Epub 2020 Jan 13. PMID: 31932802
174. Shaw AT, Riely GJ, Bang YJ, Kim DW, **Camidge DR**, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. *Ann Oncol*. 2019 Jul;30(7):1121-1126. Epub 2019 Dec 4. PMID: 31987379
175. Ng TL, Narasimhan N, Gupta N, Venkatakrishnan K, Kerstein D, **Camidge DR**. Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2020 Mar 2. pii: S1556-0864(20)30133-7. doi: 10.1016/j.jtho.2020.02.011. [Epub ahead of print] PMID: 32135189
176. Peters S, Shaw AT, Besse B, Felip E, Solomon BJ, Soo RA, Bearz A, Gadgeel SM, Lin CC, Kao S, Seto T, Masters ET, Abbattista A, Clancy JS, Thurm H, Reisman A, Peltz G, **Camidge D. Ross**. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive

- non-small cell lung cancer. *Lung Cancer*. 2020 Mar 10;144:10-19. [Epub ahead of print] PMID: 32344248
177. Patil T, Pacheco JM, Dimou A, Purcell WT, Rossi C, Bunn PA, Doebele RC, **Camidge DR**, Ferrigno L. Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. *Front Oncol*. 2020 Apr 15;10:510. [Epub ahead of print] PMID: 32351892
178. Simons EA, Smith DE, Gao D, **Camidge DR**. Variation in toxicity reporting methods for early phase lung cancer treatment trials at oncology conferences. *J Thorac Oncol*. 2020 Apr 27. [Epub ahead of print] PMID: 32353598
179. Mok T, **Camidge DR**, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, Pérol M, Ou SI, Ahn JS, Shaw AT, Bordogna W, Smoljanović V, Hilton M, Ruf T, Noé J, Peters S. Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study. *Ann Oncol*. 2020 May 11:S0923-7534(20)39796-9. [Epub ahead of print] PMID: 32418886
180. **Camidge DR**, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. *J Clin Oncol*. 2020 Aug 11. Online ahead of print. PMID: 32780660
181. Peled N, Gillis R, Kilickap S, Froesch P, Orlov S, Filippova E, Demirci U, Christopoulos P, Cicin I, Basal FB, Yilmaz C, Fedor M, Korkmaz T, Paydas S, Gautschi O, Zirtiloglu A, Eralp Y, Cinkir HY, Sezer A, Erman M, Tural D, Turna H, Mazieres J, Dudnik E, Reguart N, **Camidge DR**, Ng TL, Şenler FÇ, Beypınar İ, Yazılıtaş D, Demirkazık A, Karaoğlu A, Okutur K, Coşkun HŞ, Şendur MAN, Isikdogan A, Cabuk D, Yumuk PF, Yıldız I, Kaplan MA, Özyılkan Ö, Öztop İ, Olmez OF, Aydın K, Aydın A, Meydan N, Grinberg RD, Roisman LC. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. *Lung Cancer*. 2020 Jul 27;148:48-54. Online ahead of print. PMID: 32799090
182. Chih-Hsin Yang J, **Camidge DR**, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. Safety, Efficacy and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients with EGFR-mutated Advanced NSCLC: a Multicenter, Open-label, Phase I Trial. *J Thorac Oncol*. 2020 Sep 8:S1556-0864(20)30714-0. Online ahead of print. PMID: 32916310

183. Keeping ST, Cope S, Chan K, Wilson FR, Jansen JP, Penrod JR, Abraham P, **Camidge DR**, Korytowsky B, Gu T, Garcia AJ, Le TK, Yuan Y. Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer. *J Comp Eff Res*. 2020 Nov 3. Online ahead of print. PMID: 33140652
184. Ng TL, Johnson A, Nemenoff RA, Hsieh E, Osypuk AA, van Bokhoven A, Li H, **Camidge DR**, Schenk EL. Brief Report: Prospective observational study showing early pulmonary function changes associated with brigatinib initiation. *J Thorac Oncol*. 2020 Dec 8:S1556-0864(20)31052-2. Online ahead of print. PMID: 33307191
185. Mok T, Peters S, **Camidge DR**, Noé J, Gadgeel S, Ou SI, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT. Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. *J Thorac Oncol*. 2020 Oct 24:S1556-0864(20)30815-7. Online ahead of print. PMID: 33334571
186. Bertino EM, Gentzler RD, Clifford SE, Kolesar JM, Muzikansky A, Haura EB, Piotrowska Z, **Camidge DR**, Stinchcombe TE, Hann CL, Malhotra J, Villaruz LC, Paweletz CP, Lau CJ, Sholl LM, Takebe N, Moscow JA, Shapiro GI, Janne PA, Oxnard GR. Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903). *Clin Cancer Res*. 2020 Dec 29. Online ahead of print. PMID: 33376097
187. Felip E, Shaw AT, Bearz A, **Camidge DR**, Solomon BJ, Bauman JR, Bauer TM, Peters S, Toffalorio F, Abbattista A, Thurm H, Peltz G, Wiltshire R, Besse B. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. *Ann Oncol*. 2021 Feb 24:S0923-7534(21)00129-0. Online ahead of print. PMID: 33639216
188. **Camidge DR**, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, Shapiro GI, Socinski MA, Murphy DA, Conte U, Tang Y, Wang SC, Wilner KD, Villaruz LC. Crizotinib in Patients With MET-Amplified NSCLC. *J Thorac Oncol*. 2021 Mar 3:S1556-0864(21)01710-X. Online ahead of print. PMID: 33676017
189. Garcia Campelo MR, Lin HM, Zhu Y, Pérol M, Jahanzeb M, Popat S, Zhang P, **Camidge DR**. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naïve ALK + non-small cell lung cancer (ALTA-1L). *Lung Cancer*. 2021 Mar 9;155:68-77. Online ahead of print. PMID: 33744781
190. **Camidge DR**, Park H, Smoyer KE, Jacobs I, Lee LJ, Askerova Z, McGinnis J, Zakharia Y. Race and ethnicity representation in clinical trials: findings from a

- literature review of Phase I oncology trials. *Future Oncol.* 2021 May 28. Online ahead of print. PMID: 34047192
191. Ji J, Mitra A, **Camidge DR**, Riess JW. Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib. *Clin Lung Cancer.* 2021 Apr 27:S1525-7304(21)00092-9. Online ahead of print. PMID: 34059475
192. Drilon A, Duruisseaux M, Han JY, Ito M, Falcon C, Yang SR, Murciano-Goroff YR, Chen H, Okada M, Molina MA, Wislez M, Brun P, Dupont C, Branden E, Rossi G, Schrock A, Ali S, Gounant V, Magne F, Blum TG, Schram AM, Monnet I, Shih JY, Sabari J, Pérol M, Zhu VW, Nagasaka M, Doebele R, **Camidge DR**, Arcila M, Ignatius Ou SH, Moro-Sibilot D, Rosell R, Muscarella LA, Liu SV, Cadranel J. Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. *J Clin Oncol.* 2021 Jun 2: Online ahead of print. PMID: 34077268
193. Hann CL, Burns TF, Dowlati A, Morgensztern D, Ward PJ, Koch MM, Chen C, Ludwig C, Patel M, Nimeiri H, Komarnitsky P, **Camidge DR**. A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC. *J Thorac Oncol.* 2021 Jul 6: Online ahead of print. PMID: 34242790
194. Tsui DCC, Kavanagh BD, Honce JM, Rossi C, Patil T, **Camidge DR**. Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib. *Clin Lung Cancer.* 2021 Jun 12: Online ahead of print. PMID: 34246540
195. Do KT, Chow LQM, Reckamp K, Sanborn RE, Burris H, Robert F, **Camidge DR**, Steuer CE, Strickler JH, Weise A, Specht JM, Gutierrez M, Haughney P, Hengel S, Derleth CL, Yap TA. First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors. *Oncologist.* 2021 Jul 20. Online ahead of print. PMID: 34288257
196. Bittoni M, Yang JC, Shih JY, Peled N, Smit EF, **Camidge DR**, Arasada RR, Oksen D, Boutmy E, Stroh C, Johne A, Carbone DP, Paik PK. Real-world insights into patients with advanced NSCLC and MET alterations. *Lung Cancer.* 2021 Jul 16;159:96-106. Online ahead of print. PMID: 34320421
197. Tsui DCC, Aisner D, Nijmeh H, Bao L, Menter A, **Camidge DR**. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. *Clin Lung Cancer.* 2021 Jul 3:S1525-7304(21)00179-0. Online ahead of print. PMID: 34330640

Reviews

1. **Camidge R**, Price A. Characterizing the phenomenon of radiation recall dermatitis. *Radiotherapy and Oncology* 2001; 59:237-245. [PMID: 11369064](#)
2. **Camidge R**, Bateman DN. Self-poisoning in the UK: epidemiology and toxidromes. *Clinical Medicine* 2003; 3:111-114. [PMID: 12737364](#)
3. **Camidge DR**, Wood RJ, Bateman DN. The epidemiology of self-poisoning in the UK. *British Journal of Clinical Pharmacology* 2003; 56: 613-619. No PMID listed
4. Attina T, **Camidge R**, Newby DE, Webb DJ. Endothelin antagonism in pulmonary hypertension, heart failure and beyond. *The Heart* 2005; 91:825-831. [PMID: 15894792](#)
5. Weiss GJ, Bunn PA, **Camidge DR**. From radiotherapy to targeted therapy: Twenty years in the management of non-small cell lung cancer. *Oncology* 2006; 20:1515-1524. [PMID: 17153906](#)
6. **Camidge DR**. The potential of DR4- and DR5-directed therapies in lung cancer. *Clinical Lung Cancer* 2007; 8(7):413-419. No PMID listed
7. **Camidge DR**. Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-R2 for use in the treatment of solid tumors. *Expert Opinion on Biological Therapy* 2008; 8(8):1167-1176. [PMID: 18613768](#)
8. Call JA, Eckhardt SG, **Camidge DR**. Targeted manipulation of apoptosis in cancer treatment. *The Lancet Oncology* 2008; 9(10):1002-11. [PMID: 18760670](#)
9. Dziadziuszko R, **Camidge DR**, Hirsch, FR. The Insulin-like Growth Factor Pathway in Lung Cancer. *Journal of Thoracic Oncology* 2008; 3(8):815-818. [PMID: 19632946](#)
10. **Camidge DR**, Dziadziuszko R, Hirsch, FR. The rationale and development of therapeutic IGF-axis inhibition for lung and other cancers. *Clinical Lung Cancer* 2009; 10(4):262-272. [PMID: 19632946](#)
11. Solomon B, Varella-Garcia M, **Camidge DR**. ALK gene rearrangements: A new therapeutic target in a molecularly- defined subset of non-small cell lung cancer. *Journal of Thoracic Oncology* 2009; 4(12):1450-1454. [PMID: 20009909](#)
12. Doebele RC, Oton AB, Peled N, **Camidge DR**, Bunn PA. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. *Lung Cancer* 2010 Jan 19. [Epub ahead of print] [PMID: 20092908](#)
13. Weickhardt AJ, **Camidge DR**. The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. *Clinical Investigation*. August 2011 2011;1 (8)(8):1119-1126. No PMID listed
14. Bowles DW, O'Bryant CL, **Camidge DR**, Jimeno A. The intersection between cannabis and cancer in the United States. *Crit Rev Oncol Hematol*. 2011 Oct 19 [Epub ahead of print] [PMID: 22019199](#)

15. Kono SA, Heasley LE, Doebele RC, **Camidge DR**. Adding to the Mix: Fibroblast Growth Factor and Platelet-derived Growth Factor Receptor Pathways as Targets in Non-small Cell Lung Cancer. *Curr Cancer Drug Targets*. 2011 Oct 27. [Epub ahead of print] PMID: 22165970
16. **Camidge DR**, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. *Nature Reviews Clinical Oncology* 2012 Apr 3;9(5):268-77. PMID: 22473102
17. Bowles DB, Weickhardt AJ, Doebele RD, **Camidge DR**, Jimeno A. Crizotinib for the treatment of patients with advanced non-small cell lung cancer. *Drugs Today (Barc)*. 2012 Apr;48(4):271-82. PMID: 22536569
18. Dimberg LY, Anderson CK, **Camidge R**, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. *Oncogene* 2012 May 14. doi: 10.1038/onc.2012.164. [Epub ahead of print] PMID: 22580613
19. **DR Camidge**. ALK rearrangements as a therapeutic target in advanced non-small cell lung cancer. *International Journal of Targeted Therapies in Cancer* 2012; 6.12:30-33. No PMID listed
20. Weickhardt AJ, Aisner DL, Franklin WA, Varella-Garcia M, Doebele RC, **Camidge DR**. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. *Cancer* 2012; Dec 20. [Epub ahead of print] PMID: 23280244
21. **Camidge DR**, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. *Nature Reviews Clinical Oncology* 2014; 11(8):473-81 PMID: 24981256
22. Luke JJ, Oxnard GR, Paweletz CP, **Camidge DR**, Heymach JV, Solit DB, Johnson BE; Cell Free DNA Working Group. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. *J Natl Cancer Inst*. 2014 Aug 8;106(8). PMID: 25106647
23. Venook AP, Arcila ME, Benson AB 3rd, Berry DA, **Camidge DR**, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML. NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. *J Natl Compr Canc Netw*. 2014 Nov;12(11):1629-49. PMID: 25361808
24. Whittington MD, Atherly AJ, Boci GT, **Camidge DR**. A Primer on Health Economic Evaluations in Thoracic Oncology. *J Thorac Oncol*. 2016 Apr 11. [Epub ahead of print] PMID: 27079184
25. Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, Anders CK, Soffietti R, **Camidge DR**, Vogelbaum MA, Dunn IF, Wen PY. Updates in the management of brain metastases. *Neuro Oncol*. 2016 Aug;18(8):1043-65. PMID: 27382120

26. Drilon A, Cappuzzo F, Ignatius Ou SH, **Camidge DR**. Targeting MET in Lung Cancer: Will Expectations Finally Be MET? *J Thorac Oncol*. 2017 Jan;12(1):15-26. PMID: 27794501
 27. Morgan RL, **Camidge DR**. Reviewing RECIST in the Era of Prolonged and Targeted Therapy. *J Thorac Oncol*. 2017 Nov 4. [Epub ahead of print] PMID: 29113950
 28. Pacheco JM, **Camidge DR**. Antibody drug conjugates in thoracic malignancies. *Lung Cancer*. 2018 Oct;124:260-269. Epub 2018 Jul 19. PMID: 30268471
 29. **Camidge DR**, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. *Nat Rev Clin Oncol*. 2019 Feb 4. [Epub ahead of print]. PMID: 30718843
 30. Pacheco JM, **Camidge DR**. Is long-term survival possible for patients with stage IV ALK+ non-small cell lung cancer? *Expert Rev Respir Med*. 2019 Mar 20:1-3. [Epub ahead of print] PMID: 30892100
 31. Pacheco JM, **Camidge DR**, Doebele RC, Schenk E. A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. *Front Oncol*. 2019 Mar 29;9:195. doi: 10.3389/fonc.2019.00195. PMID: 30984621
 32. Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C, **Camidge DR**, Iwata H, Powell CA. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. *Breast Cancer Res Treat*. 2020 Aug;183(1):23-39. PMID: 32591987
-